Fate Therapeutic Stock Price, News & Analysis

Fate Therapeutics (NASDAQ: FATE) reported significant progress in its Q2 2025 financial results and clinical developments. The company's lead candidate FT819, an off-the-shelf CAR T-cell therapy, showed promising durability in treating lupus nephritis, achieving remission at 12-month follow-up. The FDA has granted RMAT designation for FT819, and discussions are underway for a potential registrational pathway.

Key financial metrics include $248.9 million in cash and investments, with an extended operational runway through 2027. Q2 revenue was $1.9 million, while operating expenses totaled $38.9 million. The company implemented cost-saving measures, including a 12% workforce reduction.

Notable pipeline developments include FDA IND allowance for FT836 targeting solid tumors, extension of the Ono Pharmaceuticals partnership, and advancement of the FT839 dual-CAR T-cell program.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement awards. The company granted stock options for 60,000 shares to one new non-executive employee at $1.06 per share, and restricted stock units (RSUs) for 60,800 shares to two new non-executive employees.

The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a four-year vesting schedule. The stock options vest 25% after one year, with remaining 75% vesting monthly over 36 months, while RSUs vest 25% annually over four years.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement equity awards. The company granted stock options for 30,000 shares at $1.12 per share to one new non-executive employee and restricted stock units (RSUs) for 37,900 shares to two new non-executive employees.

The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a 4-year vesting schedule. Stock options vest 25% after one year with remaining monthly installments over 36 months, while RSUs vest 25% annually over four years.

Fate Therapeutics announced promising clinical data for FT819, its off-the-shelf CAR T-cell therapy, in treating systemic lupus erythematosus (SLE). All three lupus nephritis patients treated with FT819 under a fludarabine-free conditioning regimen achieved Primary Efficacy Renal Response, with the first patient maintaining drug-free remission at 12 months. An extrarenal lupus patient showed disease improvement, while another patient treated without conditioning achieved and maintained Low Lupus Disease Activity State at 6 months. The therapy demonstrated favorable safety across 59 patients, with low-grade cytokine release syndrome, no neurotoxicity, and no graft-versus-host disease. The company plans to expand the program to other autoimmune conditions and has approximately 450 cryopreserved drug product bags available.

Fate Therapeutics (NASDAQ: FATE) has appointed Matthew Abernethy, M.B.A., to its Board of Directors effective May 29, 2025. Abernethy, currently CFO of Neurocrine Biosciences, brings over 15 years of experience in corporate finance and investor relations in biotech and medical devices. He replaces Timothy P. Coughlin, who stepped down from the Board. At Neurocrine Biosciences since 2017, Abernethy oversees finance, accounting, and IT functions. His previous experience includes finance roles at Zimmer Biomet Holdings and KPMG LLP. The appointment comes as Fate Therapeutics advances its pipeline of iPSC-derived off-the-shelf cellular immunotherapies, including FT819, which shows potential for treating lupus and other autoimmune diseases.

Fate Therapeutics (NASDAQ: FATE) has announced that it will present clinical data from its Phase 1 trial of FT819, an off-the-shelf CD19-targeted CAR T-cell therapy, for systemic lupus erythematosus (SLE) at the EULAR 2025 Congress in Barcelona. The study evaluates FT819's safety and activity using either a fludarabine-free conditioning regimen or maintenance therapy without conditioning.

The company will deliver an oral presentation on treating refractory SLE with their iPSC-derived therapy, along with two poster presentations focusing on next-generation CAR T-cells and CAR-NK cell therapy. These presentations highlight Fate's innovative approaches, including Sword and Shield technology and multi-antigen targeting, aimed at eliminating the need for conditioning chemotherapy and enabling outpatient treatment.

Fate Therapeutics (NASDAQ: FATE) reported Q1 2025 financial results and business updates, highlighting significant progress in its cell therapy programs. The company's lead candidate FT819, an off-the-shelf CAR T-cell therapy for systemic lupus erythematosus (SLE), received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The Phase 1 study is expanding to include additional autoimmune diseases. Financially, Fate reported $272.7 million in cash and investments, with runway through 1H27. Q1 revenue was $1.6 million, with operating expenses at $42.9 million. The company is advancing multiple programs, including FT825/ONO-8250 for solid tumors, FT836 targeting MICA/B proteins, and FT839 dual CAR T-cell program. New clinical data for FT819 will be presented at the EULAR 2025 Congress in June.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted restricted stock units (RSUs) to two new non-executive employees. The RSUs, representing 30,400 shares of common stock, were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, with 25% vesting annually, contingent on continued employment.

Fate Therapeutics announced five presentations featuring their innovative iPSC-derived off-the-shelf CAR T-cell therapy platform at the upcoming ASGCT Annual Meeting in New Orleans. The highlight is an oral presentation on FT522, their groundbreaking CD19-targeted CAR NK cell product for B-cell lymphoma treatment.

Key developments include:

• First product incorporating Alloimmune Defense Receptor (ADR) technology, designed to eliminate the need for conditioning chemotherapy
• Four additional poster presentations covering applications in autoimmune diseases, hematological malignancies, and solid tumors
• Introduction of FT836, a novel MICA/B-targeting CAR T-cell therapy for solid tumors

The presentations will showcase both clinical and preclinical data, demonstrating the company's progress in developing chemotherapy-free cell therapies across multiple indications.